Prostate cancer ablation with transrectal high-intensity focused ultrasound: Assessment of tissue destruction with contrast-enhanced US

Radiology

Volumn 259, Issue 2, 2011, Pages 583-591

  Rouvière, Olivier ^a,b,c   Glas, Ludivine ^a,b   Girouin, Nicolas ^a   Mège Lechevallier, Florence ^a   Gelet, Albert ^a,c   Dantony, Emmanuelle ^a,b   Rabilloud , Muriel ^a,b   Chapelon, Jean Yves ^a,c   Lyonnet, Denis ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LABTAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GADOTERATE MEGLUMINE; SULFUR HEXAFLUORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FIBROSIS; HUMAN; HUMAN TISSUE; MALE; NECROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIOFREQUENCY ABLATION; SCORING SYSTEM; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VASCULARIZATION;

EID: 79955011353     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11101489     Document Type: Article

References (24)

1. Poissonnier L , Chapelon JY , Rouvière O , et al. Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 2007 ; 51 (2): 381-387. (Pubitemid 44937777)
2. Uchida T , Ohkusa H , Yamashita H , et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006 ; 13 (3): 228-233.
3. Blana A , Murat FJ , Walter B , et al. First analysis of the long-term results with transrectal HIFU in patients with localised prostate cancer. Eur Urol 2008 ; 53 (6): 1194-1201.
4. Murat FJ , Poissonnier L , Rabilloud M , et al. Mid-term results demonstrate salvage highcontrast intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol 2009 ; 55 (3): 640-647.
5. Rouvière O , Souchon R , Salomir R , Gelet A , Chapelon JY , Lyonnet D. Transrectal highintensity focused ultrasound ablation of prostate cancer: Effective treatment requiring accurate imaging. Eur J Radiol 2007 ; 63 (3): 317-327. (Pubitemid 47321044)
6. Kirkham AP , Emberton M , Hoh IM , Illing RO , Freeman AA , Allen C. MR imaging of prostate after treatment with high-intensity focused ultrasound. Radiology 2008 ; 246 (3): 833-844.
7. Rouvière O , Lyonnet D , Raudrant A , et al. MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 2001 ; 40 (3): 265-274. (Pubitemid 34701896)
8. Souchon R , Rouvière O , Gelet A , et al. Visualisation of HIFU lesions using elastography of the human prostate in vivo: Preliminary results. Ultrasound Med Biol 2003 ; 29 (7): 1007-1015. (Pubitemid 36873834)
9. Curiel L , Souchon R , Rouvière O , Gelet A , Chapelon JY. Elastography for the follow-up of high-intensity focused ultrasound prostate cancer treatment: Initial comparison with MRI. Ultrasound Med Biol 2005 ; 31 (11): 1461-1468. (Pubitemid 41606261)
10. Chavrier F , Chapelon JY , Gelet A , Cathignol D. Modeling of high-intensity focused ultrasoundinduced lesions in the presence of cavitation bubbles. J Acoust Soc Am 2000 ; 108 (1): 432-440. (Pubitemid 30459086)
11. Rouvière O , Curiel L , Chapelon JY , et al. Can color doppler predict the uniformity of HIFU-induced prostate tissue destruction? Prostate 2004 ; 60 (4): 289-297. (Pubitemid 39050647)
12. Wiart M , Curiel L , Gelet A , Lyonnet D , Chapelon JY , Rouvière O. Infl uence of perfusion on high-intensity focused ultrasound prostate ablation: A first-pass MRI study. Magn Reson Med 2007 ; 58 (1): 119-127. (Pubitemid 47229924)
13. Sedelaar JP , Aarnink RG , van Leenders GJ , et al. The application of three-dimensional contrast-enhanced ultrasound to measure volume of affected tissue after HIFU treatment for localized prostate cancer. Eur Urol 2000 ; 37 (5): 559-568. (Pubitemid 30189824)
14. Schneider M. SonoVue, a new ultrasound contrast agent. Eur Radiol 1999 ; 9 (Suppl 3): S347-S348.
15. Fry FJ. Intense focused ultrasound in medicine: Some practical guiding physical principles from sound source to focal site in tissue. Eur Urol 1993 ; 23 (Suppl 1): 2-7. (Pubitemid 23147641)
16. Gelet A , Chapelon JY , Margonari J , et al. Prostatic tissue destruction by high-intensity focused ultrasound: Experimentation on canine prostate. J Endourol 1993 ; 7 (3): 249-253. (Pubitemid 23223859)
17. Madersbacher S , Pedevilla M , Vingers L , Susani M , Marberger M. Effect of highintensity focused ultrasound on human pros tate cancer in vivo. Cancer Res 1995 ; 55 (15): 3346-3351.
18. Beerlage HP , Thüroff S , Debruyne FM , Chaussy C , de la Rosette JJ. Transrectal high-intensity focused ultrasound using the Abla therm device in the treatment of localized prostate carcinoma. Urology 1999 ; 54 (2): 273-277. (Pubitemid 29367251)
19. McNeal JE. Prostatic microcarcinomas in relation to cancer origin and the evolution to clinical cancer. Cancer 1993 ; 71 (3 , Suppl): 984-991. (Pubitemid 23049621)
20. McNeal JE , Haillot O. Patterns of spread of adenocarcinoma in the prostate as related to cancer volume. Prostate 2001 ; 49 (1): 48-57.
21. McNeal JE , Redwine EA , Freiha FS , Stamey TA. Zonal distribution of prostatic adenocarcinoma: Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988 ; 12 (12): 897-906. (Pubitemid 19011040)
22. Aigner F , Pallwein L , Mitterberger M , et al. Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. BJU Int 2009 ; 103 (4): 458-463.
23. Mitterberger M , Horninger W , Pelzer A , et al. A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: Impact on prostate cancer detection. Prostate 2007 ; 67 (14): 1537-1542. (Pubitemid 47536152)
24. Uchida T , Illing RO , Cathcart PJ , Emberton M. To what extent does the prostate-specific antigen nadir predict subsequent treatment failure after transrectal high-intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? BJU Int 2006 ; 98 (3): 537-539. (Pubitemid 44185871)